Drug intelligence / Profile preview

SiVEC-IAV

Development stage: Preclinical
Lead developer: SiVec Biotechnologies
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Inhalation

Overview

SiVEC-IAV is a preclinical-stage inhaled antiviral therapeutic developed by SiVec Biotechnologies for the treatment and prevention of seasonal and pandemic influenza A. It utilizes the company's proprietary BactPac™ platform, a live biotherapeutic delivery system, to deliver short hairpin RNA (shRNA) or small interfering RNA (siRNA) directly to the respiratory tract. The mechanism of action involves RNA interference (RNAi) targeting highly conserved regions of the influenza A virus genome, thereby blocking viral replication across multiple strains. This approach is designed to provide broad-spectrum protection against evolving flu viruses by silencing essential viral sequences that are less prone to mutation.

Other names: SiVEC-IAV™

Targets

Influenza A virus nucleoprotein (NP) gene RNAInfluenza A virus polymerase acidic gene RNA

Beyond the preview

Go deeper on SiVEC-IAV.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SiVEC-IAV.

Explore the full profile